Showing results (171-180 of 276) with videos related to

Sort By:
Pageof 28
Hematological Oncology|January 19, 2020
Clinical characteristics and outcomes of relapsed follicular lymphoma after autologous stem cell transplantation in the rituximab eraPierre Sesques, Jessie Bourcier, Camille Golfier, et al.
British Journal of Haematology|March 25, 2016
A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphomaBertrand Coiffier, Catherine Thieblemont, Sophie de Guibert, et al.
Annals of Hematology|May 18, 2020
Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real lifeClara Sortais, Anne Lok, Benoit Tessoulin, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 30, 2010
Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS groupCaroline Bodet-Milin, Cyrille Touzeau, Christophe Leux, et al.
The American Journal of Surgical Pathology|March 20, 2009
Peripheral T-cell lymphomas with a follicular growth pattern are derived from follicular helper T cells (TFH) and may show overlapping features with angioimmunoblastic T-cell lymphomasYenlin Huang, Anne Moreau, Jehan Dupuis, et al.
Ejhaem|July 18, 2022
RAS mutation leading to acquired resistance to dabrafenib and trametinib therapy in a multiple myeloma patient harboring BRAF mutationBaptiste Le Calvez, Yannick Le Bris, Guillaume Herbreteau, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 26, 2013
Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysisAmandine Le Bourgeois, Catherine Mohr, Thierry Guillaume, et al.
Blood Advances|September 30, 2025
Outcome of patients with mantle cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T study by LYSA GroupMarion Aymard, Morgane Cheminant, Roch Houot, et al.
Molecular Cancer Therapeutics|January 14, 2009
Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivoRenate Burger, Steven Le Gouill, Yu-Tzu Tai, et al.
Blood|November 12, 2020
Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trialSteven Le Gouill, Franck Morschhauser, David Chiron, et al.
Pageof 28